Ratings by Guggenheim (Dana Flanders)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
6/1/2021 Valneva SE VALN New Coverage Buy
(N/A)
24.41
(28.17)
15.4% Details
5/18/2021 Impel Neuropharma IMPL New Coverage Buy
(N/A)
13.89
(14.98)
7.85% Details
3/25/2021 Horizon Therapeutics HZNP Maintain Buy
(N/A)
 
 
  Details
1/22/2021 SCYNEXIS SCYX New Coverage Buy
(N/A)
7.31
(6.91)
-5.47% Details
12/14/2020 Amneal Pharmaceuticals AMRX Upgrade Buy
(Neutral)
0.07
(97.40)
139042.86% Details
9/14/2020 Trevena TRVN New Coverage Buy
(N/A)
1.78
(1.36)
-23.6% Details
8/6/2020 Horizon Therapeutics HZNP Maintain Buy
(N/A)
 
 
  Details
7/7/2020 BELLUS Health Inc. BLU Downgrade Neutral
(Buy)
3.40
(2.94)
-13.53% Details
5/27/2020 Pacira Pharmaceuticals PCRX New Coverage Neutral
(N/A)
45.10
(60.79)
34.79% Details
5/27/2020 Heron Therapeutics HRTX New Coverage Buy
(N/A)
18.24
(11.93)
-34.59% Details
5/27/2020 Collegium Pharmaceutical COLL New Coverage Neutral
(N/A)
22.52
(25.25)
12.12% Details
5/12/2020 Amneal Pharmaceuticals AMRX Upgrade Neutral
(Sell)
0.14
(97.40)
69471.43% Details
3/10/2020 Ligand Pharma LGND New Coverage Neutral
(N/A)
107.55
(111.05)
3.25% Details
2/19/2020 Bausch Health Companies BHC Maintain Buy
(N/A)
 
 
  Details
12/2/2019 TherapeuticsMD TXMD New Coverage Buy
(N/A)
2.51
(0.98)
-60.96% Details
11/25/2019 Emergent BioSolutions EBS Maintain Buy
(N/A)
 
 
  Details
11/7/2019 ANI Pharmaceuticals ANIP Maintain Buy
(N/A)
 
 
  Details
9/30/2019 BELLUS Health Inc. BLU New Coverage Buy
(N/A)
6.48
(2.94)
-54.63% Details
9/12/2019 Endo International plc ENDP New Coverage Neutral
(N/A)
4.00
(4.61)
15.25% Details